Compare American Homes 4 Rent Class A (AMH) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Homes 4 Rent Class A vs Incyte Corporation — how do they compare? American Homes 4 Rent Class A trades at $34.07 (market cap $12.28B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and American Homes 4 Rent Class A pays a 3.87% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AMH | INCY | |
|---|---|---|
Market Cap | $12.28B | $24.54B |
Sector | Real Estate | Health |
52-Week High | $35.82 | $129.93 |
52-Week Low | $27.38 | $81.61 |
Enterprise Value | $17.35B | $20.04B |
Dividend Yield | 3.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH (American Homes 4 Rent) trades at $33.87, down 0.76% today, with a bullish technical signal and strong fundamentals. The stock exhibits consistent earnings beats, with Q2 2026 FFO of $0.49 per share exceeding estimates (Zacks Investment Research, July 30, 2026). Revenue growth trends upward, reaching $1.85 billion in 2025, while net income margin improved to 25.53% in 2026. Recent news highlights institutional interest and raised 2026 guidance, supporting positive sentiment.
The outlook for AMH remains favorable due to robust operational performance and analyst consensus, but risks include regulatory changes affecting institutional home buying and high debt levels. With a $36.45 average price target and no sell ratings, Wall Street leans bullish, though investors should monitor housing policy impacts and interest rate sensitivity.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
